Provectus Pharmaceuticals, Inc. (PVCT)

Oncology Corporate Profile

Stock Performance

0.4100
0.0000

HQ Location

7327 Oak Ridge Highway, Suite A
Knoxville, TN 37931

Company Description

Provectus Pharmaceuticals is a development-stage biopharmaceutical company that develops therapies that focus on oncology and dermatology. These therapies are designed to treat metastatic melanoma, breast cancer, and liver cancer. Provectus is currently conducting Phase II clinical trials on PV-10. PV-10 is Provectus' propriety product designed to treat metastatic melanoma. Provectus also develops many over-the-counter products consisting of antiperspirants and sterilizers. Provectus was founded in 2002.

Website: http://www.pvct.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PV-10rose bengal disodiumMelanomaIII
PV-10rose bengal disodiumBreast cancerI
PV-10rose bengal disodiumHepatocellular carcinoma (HCC)I
PV-10rose bengal disodiumNeuroendocrine tumorsI
PV-10rose bengal disodiumPediatric cancerPreclinical
PV-10rose bengal disodiumVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.pvct.com

Recent News Headlines

Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma

3/16/2016 12:04 pm

(Benzinga) Mar 16, 2016 - Provectus Biopharmaceuticals, Inc. today announced that the protocol for its phase 3 clinical trial for PV-10 as an investigational treatment for melanoma has been amended to reflect current and evolving standards of care and applicable patient population for a global study in melanoma.

Provectus Biopharmaceuticals Initiating Phase 1 Study of PV-10 in Neuroendocrine Tumors Metastatic to Liver

2/29/2016 12:06 pm

(StreetInsider) Feb 29, 2016 - Provectus Biopharmaceuticals, Inc. today announced that it is initiating a protocol titled, “A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products.”

Provectus Biopharmaceuticals Confirms First Patients Dosed in Trials of PV-10 for Melanoma

1/12/2016 12:33 pm

(Yahoo! Finance) Jan 12, 2016 - Provectus Biopharmaceuticals, Inc. today confirmed that patients have been dosed in both its Phase 3 clinical trial of PV-10, Provectus’ novel investigational drug for cancer, for Stage III locally advanced cutaneous melanoma and its Phase 1b/2 clinical trial of PV-10 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with Stage IV melanoma.

Provectus Biopharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial to Study PV-10 in Combination with Immune Check Point Inhibitor Pembrolizumab

9/23/2015 11:44 am

(Stockhouse) Sept 23, 2015 - Provectus Biopharmaceuticals, Inc. today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.

Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China

7/2/2015 11:38 am

(Yahoo! Finance) July 2, 2015 - LOI signed at ESMO GI addresses melanoma and cancers of the liver.

ASCO Research Crowdsources Major Question in Prostate Cancer Care

5/30/2015 06:03 pm

(UCCC/In the Lab blog) May 29, 2015 - The DREAM Challenge, publishing in the Journal of Clinical Oncology along with the American Society for Clinical Oncology (ASCO) Annual Meeting 2015, seeks to crowdsource an important question in the treatment of metastatic, castrate-resistant prostate cancer: who will respond to the drug docetaxel?

Provectus Biopharmaceuticals Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma

4/16/2015 12:02 pm

(NASDAQ) Apr 15, 2015 - Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.

In Swansong, FDA Chief Defends Drug Approval Process

3/30/2015 12:03 pm

(Reuters) Mar 27, 2015 - In her final speech after six years as commissioner of the U.S. Food and Drug Administration, Dr. Margaret Hamburg defended the agency's drug approval standards against critics seeking weaker regulatory standards.

Provectus Biopharmaceuticals’ Amended Protocol of PV-10 for Phase 3 Study as Treatment for Melanoma Now Available Online

3/16/2015 11:27 am

(MarketWatch) Mar 16, 2015 - Study timeline remains unchanged, IRB approval process begun; minor changes to patient eligibility, endpoint assessment and crossover of patients.

Provectus Biopharmaceuticals Met with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study

2/9/2015 11:47 am

(Yahoo! Finance) Feb 9, 2015 - Provectus Biopharmaceuticals, Inc. announced today that it has held a Type C meeting with the U.S. Food and Drug Administration to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.

Proton Therapy Shown to be Less Costly than Some Alternative Radiotherapy Techniques for Early Stage Breast Cancer

11/4/2014 06:02 am

(MD Anderson) Oct 31, 2014 - In terms of duration of treatment and cost, patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) with proton therapy versus whole breast irradiation (WBI), according to new research from The University of Texas MD Anderson Proton Therapy Center.

Ranbaxy Wins FDA Approval for Generic Blood-Pressure Drug Diovan

6/27/2014 07:01 am

(Wall Street Journal) June 27, 2014 - Ranbaxy Laboratories Ltd. won approval Thursday to produce a generic version of Novartis AG's blockbuster, blood-pressure drug Diovan, improving the Indian company's prospects after years of regulatory problems.

Biotech Stock Mailbag: Vanda, Navidea, Provectus

6/16/2014 12:07 pm

(TheStreet) June 13, 2014 - Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Stock Mailbag: Vanda, Navidea, Provectus

6/16/2014 07:00 am

(TheStreet) June 13, 2014 - Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Provectus Executive Actions Worthy of FDA, SEC Investigations

5/27/2014 11:49 am

(TheStreet) May 27, 2014 - Trading in Provectus Biopharmaceuticals remains halted early Tuesday morning following Friday's decision by the FDA to reject the company's request to grant Breakthrough Therapy Designation to the experimental melanoma drug PV-10.

Provectus Executive Actions Worthy of FDA, SEC Investigations

5/27/2014 06:04 am

(TheStreet) May 27, 2014 - Trading in Provectus Biopharmaceuticals remains halted early Tuesday morning following Friday's decision by the FDA to reject the company's request to grant Breakthrough Therapy Designation to the experimental melanoma drug PV-10.

Provectus Disappears 'Breakthrough' Drug Claim on Web Site

5/20/2014 01:00 pm

(TheStreet) May 20, 2014 - Provectus is supposed to hear back from the FDA this week about the request to grant PV-10 Breakthrough Therapy status for skin cancer. So far, Provectus has said nothing about the FDA's response.

Provectus Disappears 'Breakthrough' Drug Claim on Web Site

5/20/2014 08:00 am

(TheStreet) May 20, 2014 - Provectus is supposed to hear back from the FDA this week about the request to grant PV-10 Breakthrough Therapy status for skin cancer. So far, Provectus has said nothing about the FDA's response.

Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma

3/24/2014 12:08 pm

(Reuters) Mar 24, 2014 - Provectus Biopharmaceuticals, Inc. announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma.

Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma

3/24/2014 12:00 pm

(Reuters) Mar 24, 2014 - Provectus Biopharmaceuticals, Inc. announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma.

Israel's Gamida Cell Gets Buyout Offer From Unnamed Drugmaker

3/18/2014 12:00 pm

(Reuters) Mar 18, 2014 - Israeli developer of stem cell therapies Gamida Cell has received a buyout offer worth hundreds of millions dollars from an unnamed global pharmaceutical company, two shareholders in the company said on Tuesday.

Preliminary Findings From the Phase 2 Clinical Trial of GTx-758 in Men with Castration Resistant Prostate Cancer to Be Presented at ASCO Genitourinary Cancer Symposium

1/29/2014 11:02 am

(GTx) Jan 29, 2014 - GTx, Inc. announced today the presentation of preliminary findings from the Company’s Phase 2 clinical trial evaluating GTx-758 (Capesaris®), an oral estrogen receptor alpha agonist, in men with metastatic castrate resistant prostate cancer (CRPC) at the 2014 ASCO GU Cancer Symposium on Thursday, January 30, 2014.

Fisking Provectus' Claims About PV-10's FDA Approval Path

1/27/2014 11:52 am

(TheStreet) Jan 24, 2014 - Provectus Biopharmaceuticals now says it will submit data from its phase II study of the melanoma drug PV-10 to the FDA, seeking breakthrough therapy designation (BTD), as expected.

Fisking Provectus' Claims About PV-10's FDA Approval Path

1/27/2014 11:05 am

(TheStreet) Jan 24, 2014 - Provectus Biopharmaceuticals now says it will submit data from its phase II study of the melanoma drug PV-10 to the FDA, seeking breakthrough therapy designation (BTD), as expected.

The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly

1/23/2014 12:04 pm

(TheStreet) Jan 23, 2014 - Provectus' PV-10 has already been marginalized by better, more powerful skin cancer therapies.

The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly

1/23/2014 12:00 pm

(TheStreet) Jan 23, 2014 - Provectus' PV-10 has already been marginalized by better, more powerful skin cancer therapies.

Provectus Type C Meeting With FDA Oncology Division Held December 16, 2013

12/18/2013 11:08 am

(MarketWatch) Dec 18, 2013 - Provectus Pharmaceuticals, Inc. today announced that it held a Type C meeting with the FDA's Division of Oncology Products 2 on December 16, 2013.

Provectus Type C Meeting With FDA Oncology Division Held December 16, 2013

12/18/2013 11:00 am

(MarketWatch) Dec 18, 2013 - Provectus Pharmaceuticals, Inc. today announced that it held a Type C meeting with the FDA's Division of Oncology Products 2 on December 16, 2013.

As Cancer Rates Rise in China, Trust Remains Low

4/17/2013 12:00 pm

(New York Times) Apr 17, 2013 - At the top of the list of reasons China may be facing a cancer crisis is the crucial issue of mistrust between patient and doctor. A new article in the Journal of Oncology Practice, published by the American Society of Clinical Oncology, illustrates this problem.

ASCO President Swain Recommends Strong, Stable Federal Research Investment

3/19/2013 12:01 pm

(ASCO in Action) Mar 18, 2013 - In written testimony to Congress on March 15, ASCO President Sandra M. Swain, MD, FACP, urged legislators to support a “strong, stable federal investment” in cancer research to continue the progress being made in cancer prevention, detection, diagnosis and treatment.

Study Finds Potential to Match Tumors with Known Cancer Drugs

2/6/2013 11:05 am

(University of Michigan Health) Feb 5, 2013 - Mapping the landscape of kinases could aid in new world of personalized cancer treatment.

Provectus Pharmaceuticals Announces H. Lee Moffitt Cancer Center Initiates Phase 1 Study of PV-10 to Elucidate Bystander Effect

1/8/2013 12:10 pm

(CNBC) Jan 8, 2013 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional ("IL") PV-10 injection of melanoma tumors.

Provectus Pharmaceuticals Announces H. Lee Moffitt Cancer Center Initiates Phase 1 Study of PV-10 to Elucidate Bystander Effect

1/8/2013 12:01 pm

(CNBC) Jan 8, 2013 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional ("IL") PV-10 injection of melanoma tumors.

Navidea Biopharma Submits Lymphoseek MAA To European Medicines Agency

12/18/2012 12:00 pm

(NASDAQ/RTTNews) Dec 18, 2012 - Navidea Biopharmaceuticals Inc. announced Tuesday that it has submitted a Marketing Authorization Application or MAA for its investigational radiopharmaceutical Lymphoseek (technetium Tc 99m tilmanocept) injection, a novel intraoperative lymphatic mapping or ILM agent, to the European Medicines Agency or EMA.

Medtronic Manipulated Bone Product Data, Senators Say

10/25/2012 12:01 pm

(Bloomberg) Oct 25, 2012 - Medtronic Inc. ghost-wrote sections of medical papers and paid physician authors hundreds of millions of dollars in “consulting fees” to promote its bone-growth product Infuse, a U.S. Senate investigation found.

Cancer Disparities Between D.C. Blacks and Whites Greater Than Those Nationwide

10/23/2012 12:00 pm

(Rand Corp.) Oct 22, 2012 - Disparities in cancer between white and black residents of Washington, D.C., are wider than those nationwide, with blacks much more likely to be diagnosed with and die from cancer than their white peers, according to a new RAND Corporation study.

Provectus Pharmaceuticals Presents Final Phase 2 Melanoma Data at ESMO 2012

10/2/2012 01:01 pm

(4-traders) Oct 2, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that final top-line data from its Phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the ESMO (European Society for Medical Oncology) 2012 Congress in Vienna, Austria on October 1, 2012.

Provectus Pharmaceuticals Presents Final Phase 2 Melanoma Data at ESMO 2012

10/2/2012 01:00 pm

(4-traders) Oct 2, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that final top-line data from its Phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the ESMO (European Society for Medical Oncology) 2012 Congress in Vienna, Austria on October 1, 2012.

AstraZeneca’s Iressa Shows Benefit in Tests on Esophageal Cancer

10/1/2012 10:04 am

(Bloomberg) Sept 29, 2012 - AstraZeneca Plc’s Iressa improved quality of life in a trial on advanced esophageal cancer patients and showed a “modest” benefit in extending the time it took for the disease to worsen compared with a placebo.

Provectus Expands Protocol for Phase 1 Liver Cancer Study

9/27/2012 11:22 am

(4-traders) Sept 27, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

Provectus Expands Protocol for Phase 1 Liver Cancer Study

9/27/2012 11:02 am

(4-traders) Sept 27, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

Provectus Pharmaceuticals' Top-Line Final Phase 2 Data on PV-10 Presented at 2nd European Post-Chicago Melanoma Meeting 2012 on June 22, 2012

6/26/2012 11:55 am

(TheStreet) June 26, 2012 - Provectus Pharmaceuticals Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

Provectus Pharmaceuticals' Top-Line Final Phase 2 Data on PV-10 Presented at 2nd European Post-Chicago Melanoma Meeting 2012 on June 22, 2012

6/26/2012 11:05 am

(TheStreet) June 26, 2012 - Provectus Pharmaceuticals Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

Doug Ulman, National Cancer Survivorship Advocate, Joins Provectus Pharmaceuticals' Corporate Advisory Board

5/31/2012 12:12 pm

(Marketwatch) May 30, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has appointed Doug Ulman, President and CEO of LIVESTRONG, to its Corporate Advisory Board.

Doug Ulman, National Cancer Survivorship Advocate, Joins Provectus Pharmaceuticals' Corporate Advisory Board

5/31/2012 12:01 pm

(Marketwatch) May 30, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has appointed Doug Ulman, President and CEO of LIVESTRONG, to its Corporate Advisory Board.